These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 15198372)

  • 1. Type 1 diabetic neuropathy and C-peptide.
    Sima AA; Zhang W; Grunberger G
    Exp Diabesity Res; 2004; 5(1):65-77. PubMed ID: 15198372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathological mechanisms involved in diabetic neuropathy: can we slow the process?
    Sima AA
    Curr Opin Investig Drugs; 2006 Apr; 7(4):324-37. PubMed ID: 16625819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of C-peptide on microvascular blood flow and blood hemorheology.
    Forst T; Kunt T
    Exp Diabesity Res; 2004; 5(1):51-64. PubMed ID: 15198371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-peptide and diabetic neuropathy.
    Sima AA
    Expert Opin Investig Drugs; 2003 Sep; 12(9):1471-88. PubMed ID: 12943492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C-peptide, Na+,K(+)-ATPase, and diabetes.
    Vague P; Coste TC; Jannot MF; Raccah D; Tsimaratos M
    Exp Diabesity Res; 2004; 5(1):37-50. PubMed ID: 15198370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-peptide prevents and improves chronic Type I diabetic polyneuropathy in the BB/Wor rat.
    Sima AA; Zhang W; Sugimoto K; Henry D; Li Z; Wahren J; Grunberger G
    Diabetologia; 2001 Jul; 44(7):889-97. PubMed ID: 11508275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic neuropathy differs in type 1 and type 2 diabetes.
    Sima AA; Kamiya H
    Ann N Y Acad Sci; 2006 Nov; 1084():235-49. PubMed ID: 17151305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes.
    Kamiya H; Zhang W; Sima AA
    Ann Neurol; 2004 Dec; 56(6):827-35. PubMed ID: 15497155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-peptide improves neuropathy in type 1 diabetic BB/Wor-rats.
    Zhang W; Kamiya H; Ekberg K; Wahren J; Sima AA
    Diabetes Metab Res Rev; 2007 Jan; 23(1):63-70. PubMed ID: 16845685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Peptide reverses nociceptive neuropathy in type 1 diabetes.
    Kamiya H; Zhang W; Ekberg K; Wahren J; Sima AA
    Diabetes; 2006 Dec; 55(12):3581-7. PubMed ID: 17130507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmyelinated fiber sensory neuropathy differs in type 1 and type 2 diabetes.
    Kamiya H; Murakawa Y; Zhang W; Sima AA
    Diabetes Metab Res Rev; 2005; 21(5):448-58. PubMed ID: 15747389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin, C-peptide, hyperglycemia, and central nervous system complications in diabetes.
    Sima AA; Kamiya H; Li ZG
    Eur J Pharmacol; 2004 Apr; 490(1-3):187-97. PubMed ID: 15094085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuropathology of diabetic neuropathy and its correlations with neurophysiology.
    Sima AA; Cherian PV
    Clin Neurosci; 1997; 4(6):359-64. PubMed ID: 9358980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy.
    Ekberg K; Brismar T; Johansson BL; Lindström P; Juntti-Berggren L; Norrby A; Berne C; Arnqvist HJ; Bolinder J; Wahren J
    Diabetes Care; 2007 Jan; 30(1):71-6. PubMed ID: 17192336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. C-peptide and central nervous system complications in diabetes.
    Li ZG; Sima AA
    Exp Diabesity Res; 2004; 5(1):79-90. PubMed ID: 15198373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New aspects on biological activity of C-peptide in IDDM patients.
    Forst T; Kunt T; Pfützner A; Beyer J; Wahren J
    Exp Clin Endocrinol Diabetes; 1998; 106(4):270-6. PubMed ID: 9792458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration.
    Skundric DS; Lisak RP
    Exp Diabesity Res; 2003; 4(4):303-12. PubMed ID: 14668051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
    Casellini CM; Barlow PM; Rice AL; Casey M; Simmons K; Pittenger G; Bastyr EJ; Wolka AM; Vinik AI
    Diabetes Care; 2007 Apr; 30(4):896-902. PubMed ID: 17392551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial and neural regulation of skin microvascular blood flow in patients with diabetic peripheral neuropathy: effect of treatment with the isoform-specific protein kinase C beta inhibitor, ruboxistaurin.
    Brooks B; Delaney-Robinson C; Molyneaux L; Yue DK
    J Diabetes Complications; 2008; 22(2):88-95. PubMed ID: 18280438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The insulin-like growth factor system and neurological complications in diabetes.
    Sima AA; Li ZG; Zhang W
    Exp Diabesity Res; 2003; 4(4):235-56. PubMed ID: 14668047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.